Gossamer Bio submits first NDA, for seralutinib in PAH, to FDA
The September 2026 filing could trigger up to $125 million more in committed financing once FDA accepts it, as the company reported third quarter results.
Gossamer Bio announced on November 10, 2026 that it submitted a New Drug Application to the FDA in September 2026 for seralutinib for the treatment of pulmonary arterial hypertension, marking the company's first NDA submission.1 The application is supported by the Phase 3 PROSERA Study as the primary well-controlled trial, along with confirmatory evidence from the Phase 2 TORREY Study and additional supportive analyses.1 The FDA has not yet decided whether to accept the NDA for filing.1 Seralutinib remains investigational and is not approved by any regulatory authority.1 The company said it is focused on supporting the FDA's review and preparing for a potential commercial launch of seralutinib in 2027.1
On the corporate side, Gossamer reacquired worldwide development and commercial rights to seralutinib from Chiesi Farmaceutici S.p.A. in July 2026, terminating their prior collaboration; the deal included a one-time $5 million payment from Chiesi to Gossamer, with no upfront payment required from Gossamer, while Chiesi retains rights to a capped royalty and certain regulatory and commercial milestone payments.1
Financing tied to the regulatory timeline includes a structured private placement announced in August 2026 with potential gross proceeds up to approximately $250 million, of which about $150 million is committed across two closings; the first closing delivered about $25 million, and a second closing of up to $125 million is contingent on FDA acceptance of the NDA within 2026 and other customary conditions.1 Separate warrants tied to eventual FDA approval could add up to roughly $100 million more if exercised for cash.1
Gossamer also completed a 1-for-80 reverse stock split in September 2026 to regain compliance with Nasdaq's minimum bid price rule.1 As of quarter end, cash, cash equivalents and marketable securities totaled $51.2 million, down from $57.0 million at the end of the prior quarter.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.